ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Business

Teva Takeda Pharma shooting for $916m in sales in 2017

Japanese-Israeli joint venture's business size revealed for first time

TOKYO -- Teva Takeda Pharma is likely to post sales of slightly more than 100 billion yen ($916 million) in the year ending December, President Hiroshi Matsumori said in a speech here Friday, revealing the drugmaker's business size for the first time.

Hiroshi Matumori

The Nagoya-based company was established in 2016 as a joint venture between Takeda Pharmaceutical and Israel's Teva Pharmaceutical Industries. Off-patent drugs are expected to account for 55% of the projected sales, with generics making up the remaining 45%. Teva Takeda plans to procure more off-patent products from Takeda and release new generics.

Teva Takeda is seen to be positioned behind Nichi-Iko PharmaceuticalSawai Pharmaceutical and Towa Pharmaceutical in the generics market in Japan.

Hoping to better compete in the generics market, where price wars are raging, Teva Takeda will pursue efficiency and supply stability. The company's lineup of generics totaled some 800 products at the time of its founding, but it plans to discontinue production of about 100 of these.

The extensive generics lineup has complicated production, causing Teva Takeda to grapple with issues concerning stable supply and quality.  

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media